000			02329 a2200649 4500
005			20250516202017.0
264		0	_c20150701
008			201507s 0 0 eng d
022			_a1873-7560
024	7		_a10.1016/j.eururo.2014.02.040 _2doi
040			_aNLM _beng _cNLM
100	1		_aMcKay, Rana R
245	0	0	_aPrognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. _h[electronic resource]
260			_bEuropean urology _cSep 2014
300			_a502-9 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aAxitinib
650	0	4	_aBisphosphonate-Associated Osteonecrosis of the Jaw _xetiology
650	0	4	_aBone Density Conservation Agents _xadverse effects
650	0	4	_aBone Neoplasms _xdrug therapy
650	0	4	_aCarcinoma, Renal Cell _xdrug therapy
650	0	4	_aDiphosphonates _xadverse effects
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aHypocalcemia _xchemically induced
650	0	4	_aImidazoles _xtherapeutic use
650	0	4	_aIndazoles _xtherapeutic use
650	0	4	_aIndoles _xtherapeutic use
650	0	4	_aInterferon-alpha _xtherapeutic use
650	0	4	_aKidney Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNiacinamide _xanalogs & derivatives
650	0	4	_aPamidronate
650	0	4	_aPhenylurea Compounds _xtherapeutic use
650	0	4	_aPrognosis
650	0	4	_aPyrroles _xtherapeutic use
650	0	4	_aRenal Insufficiency _xchemically induced
650	0	4	_aRetrospective Studies
650	0	4	_aSirolimus _xanalogs & derivatives
650	0	4	_aSorafenib
650	0	4	_aSunitinib
650	0	4	_aSurvival Rate
650	0	4	_aTOR Serine-Threonine Kinases _xantagonists & inhibitors
650	0	4	_aVascular Endothelial Growth Factor A _xantagonists & inhibitors
650	0	4	_aZoledronic Acid
700	1		_aLin, Xun
700	1		_aPerkins, Julia J
700	1		_aHeng, Daniel Y C
700	1		_aSimantov, Ronit
700	1		_aChoueiri, Toni K
773	0		_tEuropean urology _gvol. 66 _gno. 3 _gp. 502-9
856	4	0	_uhttps://doi.org/10.1016/j.eururo.2014.02.040 _zAvailable from publisher's website
999			_c23625307 _d23625307